;AP/CP Templates

;Email
:*:newca\::Hi Dr. [xx], `r`rThe pathology result for your patient, [name] (DOB: [xx]), includes [diagnosis]. To our knowledge this is the patient's first diagnosis with this type of cancer. See report in EPIC. `r`rBest regards,

;ANATOMIC PATHOLOGY
;Final diagnosis blank formatting
:*:1pf\::A.  [xx] `r`t- [xx]
:*:2pf\::A.  [xx] `r`t- [xx] `r`rB.  [xx] `r`t- [xx]
:*:3pf\::A.  [xx] `r`t- [xx] `r`rB.  [xx] `r`t- [xx]`r`rC.  [xx] `r`t- [xx]
:*:4pf\::A.  [xx] `r`t- [xx] `r`rB.  [xx] `r`t- [xx]`r`rC.  [xx] `r`t- [xx] `r`rD.  [xx] `r`t- [xx]
:*:5pf\::A.  [xx] `r`t- [xx] `r`rB.  [xx] `r`t- [xx]`r`rC.  [xx] `r`t- [xx] `r`rD.  [xx] `r`t- [xx] `r`rE.  [xx] `r`t- [xx]
:*:6pf\::A.  [xx] `r`t- [xx] `r`rB.  [xx] `r`t- [xx]`r`rC.  [xx] `r`t- [xx] `r`rD.  [xx] `r`t- [xx] `r`rE.  [xx] `r`t- [xx] `r`rF.  [xx] `r`t- [xx]
:*:7pf\::A.  [xx] `r`t- [xx] `r`rB.  [xx] `r`t- [xx]`r`rC.  [xx] `r`t- [xx] `r`rD.  [xx] `r`t- [xx] `r`rE.  [xx] `r`t- [xx] `r`rF.  [xx] `r`t- [xx] `r`rG.  [xx] `r`t- [xx]
:*:8pf\::A.  [xx] `r`t- [xx] `r`rB.  [xx] `r`t- [xx]`r`rC.  [xx] `r`t- [xx] `r`rD.  [xx] `r`t- [xx] `r`rE.  [xx] `r`t- [xx] `r`rF.  [xx] `r`t- [xx] `r`rG.  [xx] `r`t- [xx] `r`rH.  [xx] `r`t- [xx]
:*:9pf\::A.  [xx] `r`t- [xx] `r`rB.  [xx] `r`t- [xx]`r`rC.  [xx] `r`t- [xx] `r`rD.  [xx] `r`t- [xx] `r`rE.  [xx] `r`t- [xx] `r`rF.  [xx] `r`t- [xx] `r`rG.  [xx] `r`t- [xx] `r`rH.  [xx] `r`t- [xx] `r`rI.  [xx] `r`t- [xx]
:*:10pf\::A.  [xx] `r`t- [xx] `r`rB.  [xx] `r`t- [xx]`r`rC.  [xx] `r`t- [xx] `r`rD.  [xx] `r`t- [xx] `r`rE.  [xx] `r`t- [xx] `r`rF.  [xx] `r`t- [xx] `r`rG.  [xx] `r`t- [xx] `r`rH.  [xx] `r`t- [xx] `r`rI.  [xx] `r`t- [xx] `r`rJ.  [xx] `r`t- [xx]
:*:11pf\::A.  [xx] `r`t- [xx] `r`rB.  [xx] `r`t- [xx]`r`rC.  [xx] `r`t- [xx] `r`rD.  [xx] `r`t- [xx] `r`rE.  [xx] `r`t- [xx] `r`rF.  [xx] `r`t- [xx] `r`rG.  [xx] `r`t- [xx] `r`rH.  [xx] `r`t- [xx] `r`rI.  [xx] `r`t- [xx] `r`rJ.  [xx] `r`t- [xx] `r`rK.  [xx] `r`t- [xx]
:*:12pf\::A.  [xx] `r`t- [xx] `r`rB.  [xx] `r`t- [xx]`r`rC.  [xx] `r`t- [xx] `r`rD.  [xx] `r`t- [xx] `r`rE.  [xx] `r`t- [xx] `r`rF.  [xx] `r`t- [xx] `r`rG.  [xx] `r`t- [xx] `r`rH.  [xx] `r`t- [xx] `r`rI.  [xx] `r`t- [xx] `r`rJ.  [xx] `r`t- [xx] `r`rK.  [xx] `r`t- [xx] `r`rL.  [xx] `r`t- [xx]
:*:13pf\::A.  [xx] `r`t- [xx] `r`rB.  [xx] `r`t- [xx]`r`rC.  [xx] `r`t- [xx] `r`rD.  [xx] `r`t- [xx] `r`rE.  [xx] `r`t- [xx] `r`rF.  [xx] `r`t- [xx] `r`rG.  [xx] `r`t- [xx] `r`rH.  [xx] `r`t- [xx] `r`rI.  [xx] `r`t- [xx] `r`rJ.  [xx] `r`t- [xx] `r`rK.  [xx] `r`t- [xx] `r`rL.  [xx] `r`t- [xx] `r`rM.  [xx] `r`t- [xx]
:*:14pf\::A.  [xx] `r`t- [xx] `r`rB.  [xx] `r`t- [xx]`r`rC.  [xx] `r`t- [xx] `r`rD.  [xx] `r`t- [xx] `r`rE.  [xx] `r`t- [xx] `r`rF.  [xx] `r`t- [xx] `r`rG.  [xx] `r`t- [xx] `r`rH.  [xx] `r`t- [xx] `r`rI.  [xx] `r`t- [xx] `r`rJ.  [xx] `r`t- [xx] `r`rK.  [xx] `r`t- [xx] `r`rL.  [xx] `r`t- [xx] `r`rM.  [xx] `r`t- [xx] `r`rN.  [xx] `r`t- [xx]
:*:15pf\::A.  [xx] `r`t- [xx] `r`rB.  [xx] `r`t- [xx]`r`rC.  [xx] `r`t- [xx] `r`rD.  [xx] `r`t- [xx] `r`rE.  [xx] `r`t- [xx] `r`rF.  [xx] `r`t- [xx] `r`rG.  [xx] `r`t- [xx] `r`rH.  [xx] `r`t- [xx] `r`rI.  [xx] `r`t- [xx] `r`rJ.  [xx] `r`t- [xx] `r`rK.  [xx] `r`t- [xx] `r`rL.  [xx] `r`t- [xx] `r`rM.  [xx] `r`t- [xx] `r`rN.  [xx] `r`t- [xx] `r`rO.  [xx] `r`t- [xx]
:*:16pf\::A.  [xx] `r`t- [xx] `r`rB.  [xx] `r`t- [xx]`r`rC.  [xx] `r`t- [xx] `r`rD.  [xx] `r`t- [xx] `r`rE.  [xx] `r`t- [xx] `r`rF.  [xx] `r`t- [xx] `r`rG.  [xx] `r`t- [xx] `r`rH.  [xx] `r`t- [xx] `r`rI.  [xx] `r`t- [xx] `r`rJ.  [xx] `r`t- [xx] `r`rK.  [xx] `r`t- [xx] `r`rL.  [xx] `r`t- [xx] `r`rM.  [xx] `r`t- [xx] `r`rN.  [xx] `r`t- [xx] `r`rO.  [xx] `r`t- [xx] `r`rP.  [xx] `r`t- [xx]
:*:17pf\::A.  [xx] `r`t- [xx] `r`rB.  [xx] `r`t- [xx]`r`rC.  [xx] `r`t- [xx] `r`rD.  [xx] `r`t- [xx] `r`rE.  [xx] `r`t- [xx] `r`rF.  [xx] `r`t- [xx] `r`rG.  [xx] `r`t- [xx] `r`rH.  [xx] `r`t- [xx] `r`rI.  [xx] `r`t- [xx] `r`rJ.  [xx] `r`t- [xx] `r`rK.  [xx] `r`t- [xx] `r`rL.  [xx] `r`t- [xx] `r`rM.  [xx] `r`t- [xx] `r`rN.  [xx] `r`t- [xx] `r`rO.  [xx] `r`t- [xx] `r`rP.  [xx] `r`t- [xx] `r`rQ.  [xx] `r`t- [xx]
:*:18pf\::A.  [xx] `r`t- [xx] `r`rB.  [xx] `r`t- [xx]`r`rC.  [xx] `r`t- [xx] `r`rD.  [xx] `r`t- [xx] `r`rE.  [xx] `r`t- [xx] `r`rF.  [xx] `r`t- [xx] `r`rG.  [xx] `r`t- [xx] `r`rH.  [xx] `r`t- [xx] `r`rI.  [xx] `r`t- [xx] `r`rJ.  [xx] `r`t- [xx] `r`rK.  [xx] `r`t- [xx] `r`rL.  [xx] `r`t- [xx] `r`rM.  [xx] `r`t- [xx] `r`rN.  [xx] `r`t- [xx] `r`rO.  [xx] `r`t- [xx] `r`rP.  [xx] `r`t- [xx] `r`rQ.  [xx] `r`t- [xx] `r`rR.  [xx] `r`t- [xx]
:*:19pf\::A.  [xx] `r`t- [xx] `r`rB.  [xx] `r`t- [xx]`r`rC.  [xx] `r`t- [xx] `r`rD.  [xx] `r`t- [xx] `r`rE.  [xx] `r`t- [xx] `r`rF.  [xx] `r`t- [xx] `r`rG.  [xx] `r`t- [xx] `r`rH.  [xx] `r`t- [xx] `r`rI.  [xx] `r`t- [xx] `r`rJ.  [xx] `r`t- [xx] `r`rK.  [xx] `r`t- [xx] `r`rL.  [xx] `r`t- [xx] `r`rM.  [xx] `r`t- [xx] `r`rN.  [xx] `r`t- [xx] `r`rO.  [xx] `r`t- [xx] `r`rP.  [xx] `r`t- [xx] `r`rQ.  [xx] `r`t- [xx] `r`rR.  [xx] `r`t- [xx] `r`rS.  [xx] `r`t- [xx]
:*:20pf\::A.  [xx] `r`t- [xx] `r`rB.  [xx] `r`t- [xx]`r`rC.  [xx] `r`t- [xx] `r`rD.  [xx] `r`t- [xx] `r`rE.  [xx] `r`t- [xx] `r`rF.  [xx] `r`t- [xx] `r`rG.  [xx] `r`t- [xx] `r`rH.  [xx] `r`t- [xx] `r`rI.  [xx] `r`t- [xx] `r`rJ.  [xx] `r`t- [xx] `r`rK.  [xx] `r`t- [xx] `r`rL.  [xx] `r`t- [xx] `r`rM.  [xx] `r`t- [xx] `r`rN.  [xx] `r`t- [xx] `r`rO.  [xx] `r`t- [xx] `r`rP.  [xx] `r`t- [xx] `r`rQ.  [xx] `r`t- [xx] `r`rR.  [xx] `r`t- [xx] `r`rS.  [xx] `r`t- [xx] `r`rT.  [xx] `r`t- [xx] 
:*:21pf\::A.  [xx] `r`t- [xx] `r`rB.  [xx] `r`t- [xx]`r`rC.  [xx] `r`t- [xx] `r`rD.  [xx] `r`t- [xx] `r`rE.  [xx] `r`t- [xx] `r`rF.  [xx] `r`t- [xx] `r`rG.  [xx] `r`t- [xx] `r`rH.  [xx] `r`t- [xx] `r`rI.  [xx] `r`t- [xx] `r`rJ.  [xx] `r`t- [xx] `r`rK.  [xx] `r`t- [xx] `r`rL.  [xx] `r`t- [xx] `r`rM.  [xx] `r`t- [xx] `r`rN.  [xx] `r`t- [xx] `r`rO.  [xx] `r`t- [xx] `r`rP.  [xx] `r`t- [xx] `r`rQ.  [xx] `r`t- [xx] `r`rR.  [xx] `r`t- [xx] `r`rS.  [xx] `r`t- [xx] `r`rT.  [xx] `r`t- [xx] `r`rU.  [xx] `r`t- [xx]
:*:22pf\::A.  [xx] `r`t- [xx] `r`rB.  [xx] `r`t- [xx]`r`rC.  [xx] `r`t- [xx] `r`rD.  [xx] `r`t- [xx] `r`rE.  [xx] `r`t- [xx] `r`rF.  [xx] `r`t- [xx] `r`rG.  [xx] `r`t- [xx] `r`rH.  [xx] `r`t- [xx] `r`rI.  [xx] `r`t- [xx] `r`rJ.  [xx] `r`t- [xx] `r`rK.  [xx] `r`t- [xx] `r`rL.  [xx] `r`t- [xx] `r`rM.  [xx] `r`t- [xx] `r`rN.  [xx] `r`t- [xx] `r`rO.  [xx] `r`t- [xx] `r`rP.  [xx] `r`t- [xx] `r`rQ.  [xx] `r`t- [xx] `r`rR.  [xx] `r`t- [xx] `r`rS.  [xx] `r`t- [xx] `r`rT.  [xx] `r`t- [xx] `r`rU.  [xx] `r`t- [xx] `r`rV.  [xx] `r`t- [xx]
:*:23pf\::A.  [xx] `r`t- [xx] `r`rB.  [xx] `r`t- [xx]`r`rC.  [xx] `r`t- [xx] `r`rD.  [xx] `r`t- [xx] `r`rE.  [xx] `r`t- [xx] `r`rF.  [xx] `r`t- [xx] `r`rG.  [xx] `r`t- [xx] `r`rH.  [xx] `r`t- [xx] `r`rI.  [xx] `r`t- [xx] `r`rJ.  [xx] `r`t- [xx] `r`rK.  [xx] `r`t- [xx] `r`rL.  [xx] `r`t- [xx] `r`rM.  [xx] `r`t- [xx] `r`rN.  [xx] `r`t- [xx] `r`rO.  [xx] `r`t- [xx] `r`rP.  [xx] `r`t- [xx] `r`rQ.  [xx] `r`t- [xx] `r`rR.  [xx] `r`t- [xx] `r`rS.  [xx] `r`t- [xx] `r`rT.  [xx] `r`t- [xx] `r`rU.  [xx] `r`t- [xx] `r`rV.  [xx] `r`t- [xx] `r`rW.  [xx] `r`t- [xx]
:*:24pf\::A.  [xx] `r`t- [xx] `r`rB.  [xx] `r`t- [xx]`r`rC.  [xx] `r`t- [xx] `r`rD.  [xx] `r`t- [xx] `r`rE.  [xx] `r`t- [xx] `r`rF.  [xx] `r`t- [xx] `r`rG.  [xx] `r`t- [xx] `r`rH.  [xx] `r`t- [xx] `r`rI.  [xx] `r`t- [xx] `r`rJ.  [xx] `r`t- [xx] `r`rK.  [xx] `r`t- [xx] `r`rL.  [xx] `r`t- [xx] `r`rM.  [xx] `r`t- [xx] `r`rN.  [xx] `r`t- [xx] `r`rO.  [xx] `r`t- [xx] `r`rP.  [xx] `r`t- [xx] `r`rQ.  [xx] `r`t- [xx] `r`rR.  [xx] `r`t- [xx] `r`rS.  [xx] `r`t- [xx] `r`rT.  [xx] `r`t- [xx] `r`rU.  [xx] `r`t- [xx] `r`rV.  [xx] `r`t- [xx] `r`rW.  [xx] `r`t- [xx] `r`rX.  [xx] `r`t- [xx]
:*:25pf\::A.  [xx] `r`t- [xx] `r`rB.  [xx] `r`t- [xx]`r`rC.  [xx] `r`t- [xx] `r`rD.  [xx] `r`t- [xx] `r`rE.  [xx] `r`t- [xx] `r`rF.  [xx] `r`t- [xx] `r`rG.  [xx] `r`t- [xx] `r`rH.  [xx] `r`t- [xx] `r`rI.  [xx] `r`t- [xx] `r`rJ.  [xx] `r`t- [xx] `r`rK.  [xx] `r`t- [xx] `r`rL.  [xx] `r`t- [xx] `r`rM.  [xx] `r`t- [xx] `r`rN.  [xx] `r`t- [xx] `r`rO.  [xx] `r`t- [xx] `r`rP.  [xx] `r`t- [xx] `r`rQ.  [xx] `r`t- [xx] `r`rR.  [xx] `r`t- [xx] `r`rS.  [xx] `r`t- [xx] `r`rT.  [xx] `r`t- [xx] `r`rU.  [xx] `r`t- [xx] `r`rV.  [xx] `r`t- [xx] `r`rW.  [xx] `r`t- [xx] `r`rX.  [xx] `r`t- [xx] `r`rY.  [xx] `r`t- [xx]
:*:26pf\::A.  [xx] `r`t- [xx] `r`rB.  [xx] `r`t- [xx]`r`rC.  [xx] `r`t- [xx] `r`rD.  [xx] `r`t- [xx] `r`rE.  [xx] `r`t- [xx] `r`rF.  [xx] `r`t- [xx] `r`rG.  [xx] `r`t- [xx] `r`rH.  [xx] `r`t- [xx] `r`rI.  [xx] `r`t- [xx] `r`rJ.  [xx] `r`t- [xx] `r`rK.  [xx] `r`t- [xx] `r`rL.  [xx] `r`t- [xx] `r`rM.  [xx] `r`t- [xx] `r`rN.  [xx] `r`t- [xx] `r`rO.  [xx] `r`t- [xx] `r`rP.  [xx] `r`t- [xx] `r`rQ.  [xx] `r`t- [xx] `r`rR.  [xx] `r`t- [xx] `r`rS.  [xx] `r`t- [xx] `r`rT.  [xx] `r`t- [xx] `r`rU.  [xx] `r`t- [xx] `r`rV.  [xx] `r`t- [xx] `r`rW.  [xx] `r`t- [xx] `r`rX.  [xx] `r`t- [xx] `r`rY.  [xx] `r`t- [xx] `r`rZ.  [xx] `r`t- [xx] 

;Common phrases
:*:masd\::microscopic examination substantiates the above cited diagnosis.
:*:nha\::no histopathologic abnormality
:*:nehm\::no evidence of hyperplasia or malignancy
:*:nedm\::no evidence of dysplasia or malignancy
:*:ned\::no evidence of dysplasia
:*:nem\::no evidence of malignancy
:*:he\::hematoxylin and eosin stained sections show
:*:bma\::biomarkers will be reported in an addendum
:*:nda\::no diagnostic abnormality
:*:ihc\::Immunohistochemistry was performed with appropriate controls for further characterization. Tumor cells are positive for [xx]; while negative for [xx].
:*:conihc\::The provided immunohistochemical stains show tumor cells positive for [xx]; while negative for [xx].
:*:ki\::ki-67 is positive in [xx]% of tumor cells.
:*:uu\::use unstained
:*:ss\::see synoptic report
:*:nw\::no waste
:*:stage\::pathologic stage (AJCC8th edition): 
:*:ci\::chronic inflammation
:*:ai\::acute inflammation
:*:aci\::acute and chronic inflammation
:*:ex\::excision
:*:rmfot\::resection margins free of tumor
:*:lvi\::lymphovascular invasion present
:*:pni\::perineural invasion present
:*:sc\::(see comment)
:*:ccr\::Clinical correlation is recommended.
:*:deeper\::Multiple deeper recuts were obtained and examined.
:*:con\::This case was reviewed in consultation with Dr.
:*:slidescan\::Select slides will be scanned for our records. All material will be returned to the referring institution.
:*:cw\::consistent with
:*:cya\::The clinical history of [xx] is noted. The examined slides my not be representative of the described clinical process. Clinical correlation is recommended.

;Lymph nodes
:*:ln\::lymph node
:*:lns\::lymph nodes
:*:mln\::Metastatic X in X of X lymph nodes (X/X)
:*:1ln\::No evidence of malignancy in one lymph node (0/1)
:*:2ln\::No evidence of malignancy in two lymph nodes (0/2)
:*:3ln\::No evidence of malignancy in three lymph nodes (0/3)
:*:4ln\::No evidence of malignancy in four lymph nodes (0/4)
:*:5ln\::No evidence of malignancy in five lymph nodes (0/5)
:*:6ln\::No evidence of malignancy in six lymph nodes (0/6)
:*:7ln\::No evidence of malignancy in seven lymph nodes (0/7)
:*:8ln\::No evidence of malignancy in eight lymph nodes (0/8)
:*:9ln\::No evidence of malignancy in nine lymph nodes (0/9)
:*:10ln\::No evidence of malignancy in ten lymph nodes (0/10)
:*:11ln\::No evidence of malignancy in eleven lymph nodes (0/11)
:*:12ln\::No evidence of malignancy in twelve lymph nodes (0/12)
:*:13ln\::No evidence of malignancy in thirteen lymph nodes (0/13)
:*:14ln\::No evidence of malignancy in fourteen lymph nodes (0/14)
:*:15ln\::No evidence of malignancy in fifteen lymph nodes (0/15)
:*:16ln\::No evidence of malignancy in sixteen lymph nodes (0/16)
:*:17ln\::No evidence of malignancy in seventeen lymph nodes (0/17)
:*:18ln\::No evidence of malignancy in eighteen lymph nodes (0/18)
:*:19ln\::No evidence of malignancy in ninteen lymph nodes (0/19)
:*:20ln\::No evidence of malignancy in twenty lymph nodes (0/20)
:*:21ln\::No evidence of malignancy in twenty-one lymph nodes (0/21)
:*:22ln\::No evidence of malignancy in twenty-two lymph nodes (0/22)
:*:23ln\::No evidence of malignancy in twenty-three lymph nodes (0/23)
:*:24ln\::No evidence of malignancy in twenty-four lymph nodes (0/24)
:*:25ln\::No evidence of malignancy in twenty-five lymph nodes (0/25)
:*:26ln\::No evidence of malignancy in twenty-six lymph nodes (0/26)
:*:27ln\::No evidence of malignancy in twenty-seven lymph nodes (0/27)
:*:28ln\::No evidence of malignancy in twenty-eight lymph nodes (0/28)
:*:29ln\::No evidence of malignancy in twenty-nine lymph nodes (0/29)
:*:30ln\::No evidence of malignancy in thirty lymph nodes (0/30)

;Autopsy
:*:apad\::GENERAL:`r`t- [body habitus, race, gender] `rWeight: [xx] kg; height: [xx] cm `rSkin [xx] in color, [cyanosis]`r[Edema]`rHair [xx], [distribution]`rEars [unremarkable]`rThorax subcutaneous fat thickness of [xx] cm, [unremarkable]`rAbdomen subcutaneous fat thickness of [xx] cm, [unremarkable]`rLower extremities [unremarkable]`rUpper extremities [unremarkable]`r`rCARDIOVASCULAR SYSTEM:`r`t- The heart is [normal, globoid] in shape, [xx] g (normal: 270-360 g males, 250-300 g females)`rTricuspid ring circumference [xx] cm (normal: 12.0-12.7 cm), [valve]`rPulmonic ring circumference [xx] cm (normal: 8.5-9.0 cm), [valve]`rMitral ring circumference [xx] cm (normal: 10.5-11.5 cm), [valve]`rAortic ring circumference [xx] cm (normal: 7.7-8.0 cm), [valve]`r`Right ventricular wall thickness [xx] cm (normal: 0.25-0.5 cm)`rLeft ventricular wall thickness [xx] cm (normal: 0.9-1.5 cm)`rRight coronary artery [xx]`rLeft anterior descending artery [xx]`rLeft circumflex artery [xx]`r[No, xx ml] pericardial effusion `r`rRESPIRATORY SYSTEM:`r`t- Right lung: [xx] g (normal: 360-570 g), [pleural effusion]`rLeft lung: [xx] g (normal: 325-480 g), [pleural effusion]`r`rHEPATOBILIARY SYSTEM:`r`t- Liver: [xx] g (normal: 1400-1900 g males, 1200-1700 g females), [unremarkable]`rGallbladder [unremarkable] `r`rGENITOURINARY SYSTEM:`r`t- Right kidney: [xx] g (normal: 125-170 g males, 115-155 g females), cortical thickness of [xx] cm`rLeft kidney: [xx] g (normal: 125-170 g males, 115-155 g females), cortical thickness of [xx] cm`r[Uterus, prostate, etc.]`r`rENDOCRINE SYSTEM:`r`t- Thyroid: [xx] g (normal: 30-70 g), [unremarkable]`rRight adrenal gland: [xx] g (normal: 5-6 g), cortical thickness of [xx] cm`rLeft adrenal gland: [xx] (normal: 5-6 g), cortical thickness of [xx] cm`r`rGASTROINTESTINAL SYSTEM:`r`t- Pancreas: [xx] g (normal: 60-135 g), [unremarkable]`rAppendix [identified, unremarkable]`r`rLYMPHATIC SYSTEM:`r`t- Spleen: [xx] g (normal: 150-200 g), [unremarkable]`r`rCENTRAL NERVOUS SYSTEM:`r`t- Brain weighs [xx] g (normal: 1250-1400 g); pituitary gland weighs [xx] g (normal: 0.5-0.6 g); `rThe brain, dura, pituitary gland, spinal cord are fixed and the findings of the cut surfaces and microscopic evaluation will be issued in an addendum.
:*:ppad\::GENERAL: `r`t- [age/race/gender] born at [gestational age] by [delivery]`rWeight: [xx] kg (normal: [xx] kg)`rCrown-heel length: [xx] cm (normal: [xx] cm)`rOccipitofrontal circumference: [xx] cm (normal: [xx] cm)`rHeel-toe length:  [xx] cm (normal: [xx] cm)`rAbdominal subcutaneous fat thickness: [xx] cm`r`rCARDIOVASCULAR SYSTEM: `r`t- Heart: [xx] g (normal: [xx] g)`r[xx] mL pericardial effusion`r`rRESPIRATORY SYSTEM:`r`t- Right lung: [xx] g; Left lung: [xx] g (normal combined lung weight: [xx] g)`rRight pleural cavity: [xx] mL, [color]`rLeft pleural cavity: [xx] mL, [color]`r`rGENITOURINARY SYSTEM:`r`t- Right kidney: [xx] g; Left kidney: [xx] g (normal: [xx] g combined)`rCortical thickness of [xx] cm`r[Uterus and ovaries/testes] [xx] g (normal: [xx] g combined)`r`rGASTROINTESTINAL SYSTEM:`r`t- [normal orientation/malrotation]`r`rHEPATOBILIARY SYSTEM:`r`t- Liver: [xx] g (normal: [xx] g), unremarkable`rGallbladder: unremarkable`rPancreas: [xx] g (normal: [xx] g), unremarkable`r`rENDOCRINE SYSTEM:`r`t- Right adrenal gland: [xx] g; Left adrenal gland: [xx] g (normal: [xx] g combined)`r`rLYMPHATIC SYSTEM:`r`t- Spleen: [xx] g (normal: [xx] g)`r`rCENTRAL NERVOUS SYSTEM:`r`t- Brain: [xx] g (normal: [xx] g)
:*:cod\::Proximal (mechanism of death): `r`t- [xx] `r`rUltimate (cause of death): `r`t- [xx] `r`rAdditional Contributing Factors: `r`t- [xx] 


;Cytology
:*:nhguc\::Negative for high grade urothelial carcinoma (NHGUC)

;Breast
:*:idcr\::- Invasive [xx] carcinoma`r`t- Tumor measures [xx] mm in greatest dimension`r`t- Histologic grade = [xx]/3 (score: tubules [xx] + nucleus [xx] + mitoses [xx] = [xx]/9) by ESBR criteria`r`t- Mitotic index = [xx]/hpf ([xx])`r`t- Lymphovascular invasion [xx]`r`t- Resection margins [xx] for invasive carcinoma (nearest = [xx] mm; location: [xx])`r`t- Ductal carcinoma in situ (DCIS)`r`t- DCIS is [xx], comprising [xx]% of total tumor, on [xx] total slides. [xx]`r`t- Nuclear grade = [xx]/3 by SBR criteria ([xx])`r`t- [xx] type`r`t- Resection margins [xx] for DCIS (nearest = [xx] mm; location:  [xx])`r`t- [xx]`r`t- See synoptic

;GYN
:*:lsil\::low grade squamous intraepithelial lesion (LSIL, CIN I)
:*:hsil\::high grade squamous intraepithelial lesion (HSIL, CIN [xx])
:*:tahbso\::Uterus and cervix, hysterectomy `r`t- [xx] `r`rOvaries and fallopian tubes, bilateral, salpingo-oophorectomy `r`t- [xx]

;Peds
:*:hpihc\::an H. pylori immunohistochemical stain was performed on block [xx] with appropriate controls and is [xx] for H pylori.
:*:placenta\::Placenta, [xx] weeks, [vaginal delivery, caesarean delivery, curettage] `r`t- [xx] grams ([xx]%ile) `r`t- Trivascular cord with no histopathologic abnormality `r`t- [Accelerated, Delayed, Appropriate for gestational age] villous maturation

;Luminal GI
:*:ta\::tubular adenoma
:*:tva\::tubulovillous adenoma
:*:hp\::hyperplastic polyp
:*:ssa\::sessile serrated adenoma/lesion
:*:fgp\::fundic gland polyp
:*:da\::duodenal adenoma
:*:eoe\::eosinophilic esophagitis ([xx] eosinophils per high power field)
:*:ciag\::chronic inactive gastritis`r`t- The results of an H. pylori immunohistochemical stain will be reported in an addendum
:*:cag\::chronic active gastritis`r`t- The results of an H. pylori immunohistochemical stain will be reported in an addendum
:*:bpm\::polypoid mucosa with no histopathologic abnormality
:*:ppi\::proton pump inhibitor
:*:reoe\::reactive squamous mucosa with increased eosinophils ([xx] per high power field)
:*:pla\::prominent lymphoid aggregate
:*:e\::esophagus
:*:s\::stomach
:*:sb\::small bowel
:*:lb\::large bowel
:*:b\::biopsy
:*:d\::duodenum
:*:ti\::terminal ileum
:*:c\::colon
:*:r\::rectum
:*:emr\::endomucosal resection
:*:gbc\::gallbladder, cholecystectomy
:*:ncm\::normal colonic mucosa
:*:ni\::normal ileal mucosa
:*:ne\::normal esophageal mucosa
:*:ndm\::normal duodenal mucosa
:*:nao\::normal antral and oxyntic mucosa

;Hepatobiliary GI
:*:lbx\::Liver, [native/allograft], needle biopsy `r`t- [xx]  `r`t- [xx] steatosis `r`t- Trichrome and reticulin stains show [xx] (stage [xx] out of 4) `r`t- Iron stain shows [no significant, minimal, mild, moderate,or severe] iron deposition in [hepatocytes, hepatocytes and Kupffer cells, or Kupffer cells] `r`t- PAS-D stain shows [no, a few, many] [small, large] intrahepatocellular globules `r`t- See comment
:*:lbxcom\::Hematoxylin and eosin stained sections show liver parenchyma with a sufficient number of portal tracts present for evaluation. Examination of the portal tracts reveals [xx](bile ducts, vessels, inflammation). The lobules show [xx] (steatosis, interface, ballooning/necrosis). [No, Mild, Moderate, or Severe] [hepatocellular, canalicular, cholangiolar] cholestasis is present. Trichrome and reticulin stains show [no fibrosis, portal fibrosis, periportal fibrosis, bridging fibrosis, and cirrhosis]. Iron stain shows [no significant, minimal, mild, moderate, or severe] iron deposition in [hepatocytes, hepatocytes and Kupffer cells, or Kupffer cells]. PAS-D stain reveals [no, few, many] [small, large] intrahepatocellular globules. 
:*:banf\::Banff score for ACR: `rPortal inflammation: Score [xx] `rBile duct inflammation damage: Score [xx] `rVenous endothelial inflammation: Score [xx] `r`rTotal RAI score: [xx] (out of 9) `r`rReference: Banff Schema for Grading Liver Allograft Rejection: An International Consensus Document. Hepatology 1997;25(3):658-63.
:*:aih\::autimmune hepatitis
:*:nash\::non-alcoholic steatohepatitis
:*:pbc\::primary biliary cirrhosis
:*:psc\::primary sclerosing cholangitis
:*:aihcom\::Overall, the features in this case include portal based hepatitis with [minimal, mild, moderate, severe] activity and [portal fibrosis, periportal fibrosis, bridging fibrosis, cirrhosis], most consistent with a clinical history of autoimmune hepatitis (positive ANA with a titer of [**] to [**] [date], positive ASMA with a titer of [**] to [**] [date], elevated IgG of [**] mg/dL (reference 700-1600) [date], elevated ALT of [**] Units/L (reference 7-55), AST of [**] Units/L (reference 10-55), total bilirubin of [**] mg/dL, relatively normal ALP of [**] Units/L (reference 30-120), and negative hepatitis A, B, and C work-up).  The patientâ€™s medication history is unremarkable. Clinical correlation is recommended.
:*:ashcom\::Overall, this biopsy shows features of steatohepatitis with [no fibrosis, stage 1, stage 2, stage 3, or cirrhosis].  The overall pattern (ballooning, Mallory hyalines, neutrophilic inflammation and cholestasis) is most consistent with clinical history of alcoholic steatohepatitis with abnormal liver function tests (elevated ALT of [**] Units/L (reference 7-55), AST of [**] Units/L (reference 10-55), total bilirubin of [**] mg/dL, relatively normal ALP of [**] Units/L (reference 30-120)). Other differential diagnosis includes Wilson disease, non-alcoholic steatohepatitis, medication/drugs (such as amiodarone), malnutrition, or a combination of the above, among others. Clinical correlation is recommended.
:*:lgrancom\::Overall, this biopsy shows non-caseating granulomatous inflammation.  Differential diagnosis is broad, including, but not limited to infectious (fungal, bacterial (including mycobacterial), and viral), medication, vasculitides, sarcoidosis, neoplasm including Hodgkin's lymphoma, autoimmune disease (such as primary biliary cholangitis (PBC)), and idiopathic granulomatous hepatitis, among others. Clinical correlation is essential to determine the etiology for the non-caseating granulomatous inflammation.
:*:nashcom\::Overall, this biopsy shows features of steatohepatitis with [no fibrosis, stage 1, stage 2, stage 3, or cirrhosis]. The overall pattern is most consistent with clinical history of nonalcoholic steatohepatitis given the presence of the following risk factors (obesity with BMI of [] kg/m2, diabetes, hyperlipidemia, hypertension), mildly elevated ALT of [**] Units/L (reference 7-55) [date], AST of [**] Units/L (reference 10-50) [date] and negative hepatitis A, B, and C work-up [date].  Other differential diagnosis include excessive alcohol use, Wilson disease, medication/drugs (such as amiodarone), malnutrition, other metabolic disease, or a combination of the above, among others. Clinical correlation is recommended.
:*:ncphcom\::Overall, this biopsy shows histological features of porto-sinusoidal vascular disease (PSVD). There is no evidence of cirrhosis. This pattern is not etiologically specific. It can be seen in patients with non-cirrhotic portal hypertension (NCPH), portal based inflammatory liver/biliary diseases such as primary biliary cholangitis, prothrombotic status, viral infections (such as HIV), drugs (azathioprine, oxaliplatin, etc), autoimmune diseases, metabolic diseases (such as NAFLD, ASH), sickle cell disease, sequelae of portal vein thrombosis, etc. It can also be seen in patients before the development of NCPH but the literature on this topic is very limited. Final diagnosis of NCPH/PSVD needs a synthesis of clinical, radiographic, and histologic findings. Clinical correlation with symptoms and signs of portal hypertension and hepatic venous hemodynamics studies are essential.
:*:pbccom\::Overall, the features in this case include granulomatous destructive cholangiolitis (florid duct lesion), consistent with primary biliary cholangitis in the context of positive anti-mitochondrial antibody (AMA) at titer (date), elevated IgM (level and date), elevated alkaline phosphatase (ALP) at level (date) and GGT level (date).  There is no histologic evidence of significant hepatitis to suggest a PBC/AIH overlap syndrome. Clinical correlation is recommended.
:*:psccom\::Overall, the features in this case include cholestasis, ductular reaction, portal edema and fibrosis, features consistent with primary sclerosing cholangitis in the context of radiographic finding showing abnormalities of the extrahepatic biliary tree, elevated alkaline phosphatase at level (date), and the presence of inflammatory bowel disease. There is no histologic evidence of autoimmune hepatitis to suggest a PSC/AIH overlap syndrome. Clinical correlation is recommended.
:*:voocom\::Overall, this biopsy shows features of hepatic venous outflow obstruction with [no fibrosis, stage 1, stage 2, stage 3, or cirrhosis].  The overall pattern is most consistent with a clinical history of [congestive heart failure, Budd-Chari syndrome]. Clinical correlation is recommended.

;GU
:*:rbl\::right base lateral
:*:rbm\::right base medial
:*:rml\::right mid lateral
:*:rmm\::right mid medial
:*:ral\::right apex lateral
:*:ram\::right apex medial
:*:lbl\::left base lateral
:*:lbm\::left base medial
:*:lml\::left mid lateral
:*:lmm\::left mid medial
:*:lal\::left apex lateral
:*:lam\::left apex medial
:*:pr\::prostate
:*:bpt\::benign prostatic tissue
:*:bph\::benign prostatic hyperplasia
:*:asap\::atypical small acinar proliferation
:*:epe\::extraprostatic extension present
:*:prbx12\::A.  Prostate, right base lateral, biopsy `r`t- [xx] `r`rB.  Prostate, right base medial, biopsy `r`t- [xx] `r`rC.  Prostate, right mid lateral, biopsy `r`t- [xx] `r`rD.  Prostate, right mid medial, biopsy `r`t- [xx] `r`rE.  Prostate, right apex lateral, biopsy `r`t- [xx] `r`rF.  Prostate, right apex medial, biopsy `r`t- [xx] `r`rG.  Prostate, left apex lateral, biopsy `r`t- [xx] `r`rH.  Prostate, left apex medial, biopsy `r`t- [xx] `r`rI.  Prostate, left mid lateral, biopsy `r`t- [xx] `r`rJ.  Prostate, left mid medial, biopsy `r`t- [xx] `r`rK.  Prostate, left base lateral, biopsy `r`t- [xx] `r`rL.  Prostate, left base medial, biopsy `r`t- [xx] `r`rM.  Prostate, MRI suspicious lesion, biopsy `r`t- [xx]
:*:prbx10\::A.  Prostate, right posterior medial, biopsy `r`t- [xx] `r`rB.  Prostate, right posterior lateral, biopsy `r`t- [xx] `r`rC.  Prostate, right base, biopsy `r`t- [xx] `r`rD.  Prostate, right anterior medial, biopsy `r`t- [xx] `r`rE.  Prostate, right anterior lateral, biopsy `r`t- [xx] `r`rF.  Prostate, left posterior medial, biopsy `r`t- [xx] `r`rG.  Prostate, left posterior lateral, biopsy `r`t- [xx] `r`rH.  Prostate, left base, biopsy `r`t- [xx] `r`rI.  Prostate, left anterior medial, biopsy `r`t- [xx] `r`rJ.  Prostate, left anterior lateral, biopsy `r`t- [xx] 
:*:pckt\::neoplastic glands are positive for AMACR, while surrounding them, p63 is negative, indicating a loss of basal cells.

;CT
:*:hnbx\::Heart, allograft, endomyocardial biopsy `r`t- ISHLT grade 0R `r`t- No evidence of acute cellular rejection `r`t- No histologic features suggestive of antibody mediated rejection
:*:lnbx\::Lung, allograft, [xx], transbronchial biopsy `r`t- No evidence of acute cellular rejection (grade A0, B0) `r`t- No histologic lesions diagnostic for chronic airway rejection (grade C0) `r`t- No evidence of infection `r`t- No features suggestive of antibody mediated rejection
:*:c4d\::the results of C4d and CD68 immunohistochemical stains will be reported in an addendum
:*:amr\::antibody mediated rejection

;BST
:*:ot\::organizing thrombus
:*:jcihc\::Immunohistochemical studies (single antibody procedures with appropriate controls) were performed, and show
:*:sarcoma\:: - [xx], FNCLCC grade [xx] of 3 `r`t- Tumor size: [xx] cm `r`t- Mitotic count: [xx]/10 hpf `r`t- Tumor necrosis: [xx] `r`t- Resection margins: [xx] `r`t- See comment and synoptic
:*:aka\::above knee amputation
:*:bka\::below knee amputation
:*:st\::soft tissue

;Heme
:*:nmlmar\::normocellular marrow with maturing trilineage hematopoiesis

;ENT
:*:smg\::submandibular gland
:*:usmg\::unremarkable submandibular gland
:*:sccwdkt\::squamous cell carcinoma, well differentiated, keratinizing type
:*:sccmdkt\::squamous cell carcinoma, moderately differentiated, keratinizing type
:*:sccpdkt\::squamous cell carcinoma, poorly differentiated, keratinizing type
:*:sccnkt\::squamous cell carcinoma, nonkeratinizing type
:*:p16scc\::p16 positive squamous cell carcinoma, nonkeratinizing type
:*:doi\::depth of invasion is
:*:ene\::extranodal extension identified
:*:niftp\::noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP)
:*:niftpcom\::The tumor classification of NIFTP refers to an encapsulated thyroid neoplasm with follicular-patterned morphology and variable nuclear atypia, lacking capsular or vascular invasion. In the current WHO classification of thyroid neoplasms, the tumor is a non-invasive, encapsulated follicular variant of papillary thyroid carcinoma. However, recent evidence has shown this tumor type to be biologically indolent. A consensus panel of the Endocrine Pathology Society has recently reclassified these lesions based upon reported findings in the literature over the past decade (Ref). The conclusion was that these lesions behave in an indolent fashion, and therefore, should be no longer classified as carcinomas, although broader validation is still pending. Treatment by thyroid lobectomy with no additional therapy other than clinical follow up appears sufficient in the appropriate clinical context.
:*:p16pend\::A p16 immunostain (as a surrogate marker for HPV-related oropharyngeal squamous cell carcinoma) is pending and the results will be reported in an addendum.
:*:p16con\::Material has been requested in order to perform p16 immunohistochemistry (as a surrogate marker for HPV-related oropharyngeal squamous cell carcinoma). If received, the results will be reported in an addendum.
:*:p16pos\::The p16 immunostain (performed with appropriate controls) is positive.
:*:p16neg\::The p16 immunostain (performed with appropriate controls) is negative.
:*:p16poscup\::Sections show nonkeratinizing squamous cell carcinoma. A p16 immunostain (performed with appropriate controls) is positive. Metastatic p16 positive squamous cell carcinomas with nonkeratinizing morphology in this location (level II/III) most commonly, but not always, arise in the oropharynx, especially the tonsils or base of tongue.
:*:gms\::a GMS stain was performed on block [xx] with appropriate controls and is [xx] for fungal organisms.
:*:aifs\::acute invasive fungal sinusitis
:*:ptp\::parathyroid tissue present
:*:hpt\::hypercellular parathyroid
:*:lh\::lymphoid hyperplasia
:*:wdscc\::invasive well-differentiated squamous cell carcinoma
:*:kt\::keratinizing type
:*:nkt\::nonkeratinizing type
:*:mdscc\::invasive moderately-differentiated squamous cell carcinoma
:*:scc\::squamous cell carcinoma
:*:mdpdscc\:: invasive moderately to poorly-differentiated squamous cell carcinoma
:*:pdscc\::invasive poorly-differentiated squamous cell carcinoma
:*:vcp\::vocal cord polyp
:*:ip\::inflammatory polyp
:*:nh\::nodular hyperplasia
:*:ofib\::oral fibroma
:*:misd\::mild squamous dysplasia
:*:mosd\::moderate squamous dysplasia
:*:ssd\::severe squamous dysplasia
:*:fbgcr\::foreign body giant cell reaction
:*:okc\::odontogenic keratocyst
:*:sqpap\::squamous papilloma
:*:sm\::squamous mucosa
:*:snm\::sinonasal mucosa
:*:undiffca\::undifferentiated carcinoma
:*:ptc\::papillary thyroid carcinoma
:*:mtc\::medullary thyroid carcinoma
:*:mildlt\::mild nonspecific lymphocytic thyroiditis
:*:chronlt\::chronic lymphocytic thyroiditis
:*:cwgraves\::diffuse hyperplasia, consistent with treated Graves disease
:*:largmet\::largest metastasis =
:*:ete\::extrathyroidal extension identified
:*:cis\::carcinoma in situ
:*:sccis::squamous cell carcinoma in-situ

:*:oc\::oral cavity
:*:np\::nasopharynx
:*:op\::oropharynx
:*:hph\::hypopharynx
:*:p\::pharynx
:*:l\::larynx

:*:lnl1b\::Lymph node, level IA, neck dissection
:*:lnl1l\::Lymph node, left level I, neck dissection
:*:lnl1bl\::Lymph node, left level IB, neck dissection
:*:lnl2l\::Lymph node, left level II, neck dissection
:*:lnl2al\::Lymph node, left level IIA, neck dissection
:*:lnl2bl\::Lymph node, left level IIB, neck dissection
:*:lnl3l\::Lymph node, left level III, neck dissection
:*:lnl4l\::Lymph node, left level IV, neck dissection
:*:lnl5l\::Lymph node, left level V, neck dissection
:*:lnl1r\::Lymph node, right level I, neck dissection
:*:lnl1br\::Lymph node, right level IB, neck dissection
:*:lnl2r\::Lymph node, right level II, neck dissection
:*:lnl2ar\::Lymph node, right level IIA, neck dissection
:*:lnl2br\::Lymph node, right level IIB, neck dissection
:*:lnl3r\::Lymph node, right level III, neck dissection
:*:lnl4r\::Lymph node, right level IV, neck dissection
:*:lnl5r\::Lymph node, right level V, neck dissection

:*:metkscc\::metastatic keratinizing squamous cell carcinoma
:*:metscc\::metastatic squamous cell carcinoma
:*:metnkscc\::metastatic nonkeratinizing squamous cell carcinoma
:*:pa\::pleomorphic adenoma
:*:wt\::Warthin tumor
:*:mec\::mucoepidermoid carcinoma
:*:plga\::polymorphous adenocarcinoma, low grade
:*:acc\::adenoid cystic carcinoma
:*:acic\::acinic cell carcinoma
:*:secca\::secretory carcinoma
:*:bca\::basal cell adenoma
:*:bcc\::basal cell carcinoma
:*:candida\::Fungal organisms morphologically consistent with Candida identified
:*:af\::(AFR1)
:*:bf\::(BFR1)
:*:cf\::(CFR1)
:*:df\::(DFR1)
:*:ef\::(EFR1)
:*:ff\::(FFR1)
:*:gf\::(GFR1)
:*:hf\::(HFR1)
:*:if\::(IFR1)
:*:jf\::(JFR1)
:*:kf\::(KFR1)
:*:lf\::(LFR1)
:*:mf\::(MFR1)
:*:nf\::(NFR1)
:*:of\::(OFR1)
:*:pf\::(PFR1)
:*:qf\::(QFR1)
:*:rf\::(RFR1)
:*:sf\::(SFR1)
:*:tf\::(TFR1)
:*:uf\::(UFR1)
:*:vf\::(VFR1)
:*:wf\::(WFR1)
:*:xf\::(XFR1)
:*:yf\::(YFR1)
:*:zf\::(ZFR1)
:*:aaf\::(AAFR1)
:*:abf\::(ABFR1)
:*:acf\::(ACFR1)
:*:adf\::(ADFR1)
:*:aef\::(AEFR1)
:*:aff\::(AFFR1)
:*:agf\::(AGFR1)
:*:ahf\::(AHFR1)
:*:aif\::(AIFR1)
:*:ajf\::(AJFR1)
:*:akf\::(AKFR1)
:*:alf\::(ALFR1)
:*:amf\::(AMFR1)
:*:anf\::(ANFR1)
:*:aof\::(AOFR1)
:*:apf\::(APFR1)
:*:clt\::chronic lymphocytic thyroiditis

;CLINICAL PATHOLOGY
;Molecular

;Transfusion Medicine

;LIST OF FUNCTIONS
:*:date\::  ;Replaces "date\" with the current date and time via the commands below.
FormatTime, CurrentDateTime,, M/d/yyyy h:mm tt ; format of date and time
SendInput %CurrentDateTime%
return

;Close program with ctrl+j
^j::ExitApp